Bayer: subsidiary Vividion acquires Tavros Therapeutics

(CercleFinance.com) - Vividion Therapeutics, a subsidiary of Bayer, announced on Wednesday the acquisition of Tavros Therapeutics, a US company specializing in precision oncology.


Vividion - which has been working with Tavros for the past two years as part of a strategic collaboration - explains that the operation will enable it to strengthen its genomic analysis capabilities.

Vividion and Tavros, who were already cooperating in the identification of proteins at the origin of cancer, now want to work together on the vulnerabilities of tumor cells, with the aim of developing adapted drugs.

The financial terms of the acquisition were not disclosed.

Copyright (c) 2025 CercleFinance.com. All rights reserved.